ACUMEN PHARMACEUTICALS INC (ABOS) competitors & alternatives
Health Care · NASDAQ
ACUMEN PHARMACEUTICALS INC (ABOS)'s top competitors and alternatives — its most similar public companies — include Biogen (BIIB), Lilly (Eli) (LLY), Regeneron Pharmaceuticals (REGN), BICARA THERAPEUTICS INC (BCAX), AVALO THERAPEUTICS INC (AVTX), ORUKA THERAPEUTICS INC (ORKA), SAB BIOTHERAPEUTICS INC (SABS), Cue Biopharma, Inc. (CUE), CONTEXT THERAPEUTICS INC (CNTX), TRISALUS LF SC CM A (TLSI), ARTIVA BIOTHERAPEUTICS INC (ARTV) and REPLIMUNE GROUP INC (REPL). These are ACUMEN PHARMACEUTICALS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top ABOS competitors & alternatives
-
BiogenBIIBHealth Care
Biogen is a global biotechnology company developing and commercializing therapies across neurology, immunology, and rare genetic disease.
$197.74 (as of 2026-07-22) · market cap $29.8B
-
Lilly (Eli)LLYHealth Care
A global pharmaceutical powerhouse developing innovative medicines across cardiometabolic, oncology, and immunology with blockbuster GLP-1 and weight-loss…
$1,163.01 (as of 2026-07-22) · market cap $1.09T
-
Regeneron PharmaceuticalsREGNHealth Care
Regeneron develops and commercializes monoclonal antibody and other biologics therapies across immunology, oncology, infectious disease, and other therapeutic…
$651.18 (as of 2026-07-22) · market cap $70.6B
-
BICARA THERAPEUTICS INCBCAXHealth Care
Bicara Therapeutics is developing a pipeline of bifunctional antibodies that precisely target and neutralize both EGFR and TGF-β pathways to improve treatment…
$27.96 (as of 2026-07-22) · market cap $1.9B
-
AVALO THERAPEUTICS INCAVTXHealth Care
Clinical-stage biotech developing abdakibart, a humanized anti-IL-1β antibody for hidradenitis suppurativa with Phase 2 data readout expected mid-2026.
$18.15 (as of 2026-07-22) · market cap $961M
-
ORUKA THERAPEUTICS INCORKAHealth Care
Clinical-stage biopharmaceutical company developing novel monoclonal antibodies with extended half-life for inflammatory and immunology indications, led by…
$92.53 (as of 2026-07-22) · market cap $5.6B
-
SAB BIOTHERAPEUTICS INCSABSHealth Care
SAB Biotherapeutics produces fully human polyclonal antibodies via engineered cattle to treat autoimmune diseases, with SAB-142 in Phase 2b trials for type 1…
$3.58 (as of 2026-07-22) · market cap $278M
-
Cue Biopharma, Inc.CUEHealth Care
Cue Biopharma engineers injectable biologics that selectively modulate disease-specific T cells to restore immune tolerance in autoimmune diseases and activate…
$34.20 (as of 2026-07-22) · market cap $144M
-
CONTEXT THERAPEUTICS INCCNTXHealth Care
Clinical-stage biopharmaceutical company developing T-cell engaging bispecific antibodies to treat solid tumors by redirecting immune cells against cancer…
$0.61 (as of 2026-07-22) · market cap $56M
-
TRISALUS LF SC CM ATLSIHealth Care
TriSalus is a medical technology company integrating proprietary pressure-enabled drug delivery devices with immunotherapeutics to improve outcomes for…
$4.24 (as of 2026-07-22) · market cap $267M
-
ARTIVA BIOTHERAPEUTICS INCARTVHealth Care
Artiva Biotherapeutics develops allogeneic natural killer cell immunotherapies for cancer, with its lead candidate AlloNK advancing through clinical trials.
$10.02 (as of 2026-07-22) · market cap $487M
-
REPLIMUNE GROUP INCREPLHealth Care
Replimune is developing engineered oncolytic viruses that directly kill tumors while triggering systemic anti-tumor immunity, with its lead candidate RP1 in…
$10.75 (as of 2026-07-22) · market cap $918M
Not quite? Describe exactly what you want →
Peers are ACUMEN PHARMACEUTICALS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: ACUMEN PHARMACEUTICALS INC (ABOS).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.